Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Osteoporosis

  Free Subscription


11.11.2019

3 J Bone Miner Res
1 J Clin Endocrinol Metab
2 J Natl Cancer Inst
2 Lancet Diabetes Endocrinol
3 Menopause
1 Osteoporos Int
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    J Bone Miner Res

  1. OCHS-BALCOM HM, Hovey KM, Andrews C, Cauley JA, et al
    Short Sleep Is Associated With Low Bone Mineral Density and Osteoporosis in the Women's Health Initiative.
    J Bone Miner Res. 2019 Nov 6. doi: 10.1002/jbmr.3879.
    PubMed     Text format     Abstract available

  2. CHU L, Liu X, He Z, Han X, et al
    Articular cartilage degradation and aberrant subchondral bone remodeling in patients with osteoarthritis and osteoporosis.
    J Bone Miner Res. 2019 Nov 6. doi: 10.1002/jbmr.3909.
    PubMed     Text format     Abstract available

  3. JIN H, Ma X, Liu Y, Yin X, et al
    Back Pain-Inducing Test, a novel and sensitive screening test for painful osteoporotic vertebral fractures: A prospective clinical study.
    J Bone Miner Res. 2019 Nov 6. doi: 10.1002/jbmr.3912.
    PubMed     Text format     Abstract available


    J Clin Endocrinol Metab

  4. HALPER-STROMBERG E, Gallo T, Champakanath A, Taki I, et al
    Bone Mineral Density across the Life-Span in Patients with Type 1 Diabetes.
    J Clin Endocrinol Metab. 2019 Nov 2. pii: 5611085. doi: 10.1210.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  5. BRUFSKY A, Mathew A
    Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does It Matter?
    J Natl Cancer Inst. 2019 Nov 6. pii: 5613898. doi: 10.1093.
    PubMed     Text format    

  6. GRALOW JR, Barlow WE, Paterson AHG, Miao JL, et al
    Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.
    J Natl Cancer Inst. 2019 Oct 31. pii: 5613900. doi: 10.1093.
    PubMed     Text format     Abstract available


    Lancet Diabetes Endocrinol

  7. STATHAM LA, Aspray TJ
    Odanacatib: the best osteoporosis treatment we never had?
    Lancet Diabetes Endocrinol. 2019 Oct 29. pii: S2213-8587(19)30348.
    PubMed     Text format    

  8. MCCLUNG MR, O'Donoghue ML, Papapoulos SE, Bone H, et al
    Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    Lancet Diabetes Endocrinol. 2019 Oct 29. pii: S2213-8587(19)30346.
    PubMed     Text format     Abstract available


    Menopause

  9. ZHOU K, Qiao X, Cai Y, Li A, et al
    Lower circulating irisin in middle-aged and older adults with osteoporosis: a systematic review and meta-analysis.
    Menopause. 2019;26:1302-1310.
    PubMed     Text format     Abstract available

  10. TAGUCHI A, Shiraki M, Tanaka S, Ohshige H, et al
    Improved periodontal disease and prevention of tooth loss in osteoporosis patients receiving once-yearly zoledronic acid: a randomized clinical trial.
    Menopause. 2019;26:1277-1283.
    PubMed     Text format     Abstract available

  11. YANG L, Hu X, Zhang H, Pan W, et al
    Association of bone mineral density with a first-degree family history of diabetes in normoglycemic postmenopausal women.
    Menopause. 2019;26:1284-1288.
    PubMed     Text format     Abstract available


    Osteoporos Int

  12. WANG Y, Yu S, Hsu C, Tsai C, et al
    Underestimated fracture risk in postmenopausal women-application of the hybrid intervention threshold.
    Osteoporos Int. 2019 Nov 6. pii: 10.1007/s00198-019-05201.
    PubMed     Text format     Abstract available


    PLoS One

  13. BAE IS, Kim JM, Cheong JH, Han MH, et al
    Association between cerebral atrophy and osteoporotic vertebral compression fractures.
    PLoS One. 2019;14:e0224439.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: